AGL 38.02 Increased By ▲ 0.77 (2.07%)
AIRLINK 122.51 Decreased By ▼ -1.51 (-1.22%)
BOP 5.77 Increased By ▲ 0.15 (2.67%)
CNERGY 3.71 Decreased By ▼ -0.01 (-0.27%)
DCL 8.48 Increased By ▲ 0.23 (2.79%)
DFML 39.90 Decreased By ▼ -0.37 (-0.92%)
DGKC 85.50 Decreased By ▼ -0.24 (-0.28%)
FCCL 33.15 Increased By ▲ 0.55 (1.69%)
FFBL 66.00 Decreased By ▼ -0.50 (-0.75%)
FFL 9.94 Decreased By ▼ -0.22 (-2.17%)
HUBC 104.85 Increased By ▲ 1.75 (1.7%)
HUMNL 13.36 Decreased By ▼ -0.04 (-0.3%)
KEL 4.36 Increased By ▲ 0.11 (2.59%)
KOSM 7.05 Decreased By ▼ -0.13 (-1.81%)
MLCF 37.80 Decreased By ▼ -0.50 (-1.31%)
NBP 60.39 Decreased By ▼ -4.62 (-7.11%)
OGDC 172.99 Decreased By ▼ -0.81 (-0.47%)
PAEL 24.80 Decreased By ▼ -0.10 (-0.4%)
PIBTL 5.75 Decreased By ▼ -0.05 (-0.86%)
PPL 142.20 Decreased By ▼ -0.50 (-0.35%)
PRL 22.95 Decreased By ▼ -0.03 (-0.13%)
PTC 15.00 Decreased By ▼ -0.11 (-0.73%)
SEARL 65.84 Increased By ▲ 0.49 (0.75%)
TELE 7.04 Increased By ▲ 0.04 (0.57%)
TOMCL 35.71 Decreased By ▼ -1.20 (-3.25%)
TPLP 7.30 Decreased By ▼ -0.04 (-0.54%)
TREET 14.22 Decreased By ▼ -0.06 (-0.42%)
TRG 50.50 Increased By ▲ 0.80 (1.61%)
UNITY 26.15 No Change ▼ 0.00 (0%)
WTL 1.23 Decreased By ▼ -0.01 (-0.81%)
BR100 9,580 Decreased By -21.4 (-0.22%)
BR30 28,513 Decreased By -60.4 (-0.21%)
KSE100 90,085 Decreased By -201.3 (-0.22%)
KSE30 28,161 Decreased By -181.6 (-0.64%)

Atomic medicine has "fantastic potential" for fighting deadly, difficult to treat cancers, the head of French nuclear giant Areva's medical arm told AFP in an interview. "We are interested in tumors against which the current therapeutic arsenal is very limited - like ovarian, gastric and pancreatic cancers - where the needs are huge and patients are waiting," explained Areva Med chief Patrick Bourdet.
Based in a Maryland suburb of the US capital, not far from the National Institutes of Health, Areva Med is pitting its hopes on a rare radioactive isotope that may be capable of selectively annihilating cancer cells.
This new weapon against these aggressive cancers is a variety of lead: the isotope Pb 212. It is extremely rare, extracted from an equally rare metal called thorium.
Only the few major nuclear powers have stocks of the radioactive metal - France, being one of them, with a considerable cache, Bourdet told AFP.
France's stock can be traced back half a decade to its nuclear subsidiary.
At that time, the Commissary of Atomic Energy, or CEA, a government-funded research group, decided to hold on to thorium after it extracted uranium - which has become the principal material used in nuclear power plants.
In 2003, researchers had the idea of extracting the isotope Pb 212 from the thorium, with Areva's scientists among them, looking in part for possible applications against cancer.
Convinced of the great medical potential of this isotope, Areva created its medical affiliate in 2009 in the United States, which, since then, hasn't stopped growing.
In 2011, Areva Med, working with researchers from the University of Alabama, got the green light from the US Food and Drug Administration to start a phase one clinical trial with Pb 212, using radioimmunotherapy.
The first patient, of 18 slated in the trial, was treated in April 2012.
"The trials are advancing in a satisfactory way," Bourdet said, adding that he couldn't be more optimistic at this point.
Backing up that optimism, Areva Med has gone into overdrive, putting in place the necessary components for the development and production of this new cancer-fighting tool, including in 2012 Areva Med inking an agreement with Swiss pharmaceutical giant Roche, the world leader in oncology.

Copyright Agence France-Presse, 2013

Comments

Comments are closed.